Agilus Diagnostics, Lucence partner to advance cancer testing services in India

Agilus Diagnostics, and Lucence, a molecular diagnostics company, announced a strategic collaboration to advance cancer diagnostics and personalised medicine in India. This collaboration aims to integrate Lucence’s molecular testing technologies into Agilus’ laboratory network, offering cancer detection, treatment selection, and monitoring capabilities.

Through this collaboration, Agilus Diagnostics will integrate Lucence’s molecular testing solutions into its oncology diagnostics portfolio. LiquidHALLMARK is an ultra-sensitive, next-generation sequencing liquid biopsy that analyses circulating tumour DNA (ctDNA) and circulating tumour RNA (ctRNA) for clinically relevant biomarkers across various cancers. LiquidHALLMARK profiles actionable somatic mutations in 80 ctDNA genes and 37 ctRNA fusions.

Lucence’s proprietary technology will empower Agilus Diagnostics to expand its oncology capabilities, offering liquid biopsy-based screening for early cancer detection, recurrence monitoring, and therapy personalisation. By integrating these pioneering tests into its extensive network of laboratories, Agilus Diagnostics aims to enhance the accessibility of precision oncology across India.